Cargando…

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)

Detalles Bibliográficos
Autores principales:	Ferris, Robert L, Kansy, Benjamin A, Gibson, Sandra Poveda, Srivastava, Raghvendra M, Bryan, James Kyle, Hershberg, Robert M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645263/ http://dx.doi.org/10.1186/2051-1426-3-S2-P144

Ejemplares similares

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
por: Li, Jing, et al.
Publicado: (2015)

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

Comparison of immune modulation by TLR8 agonist vtx-2337 (motolimod) in cancer patients and healthy volunteers
por: Dietsch, Greg, et al.
Publicado: (2014)

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer
por: Lu, Shanhong, et al.
Publicado: (2018)

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
por: Srivastava, Raghvendra M, et al.
Publicado: (2013)

Paucity of HPV-Related Head and Neck Cancers (HNC) in Nigeria
por: Oga, Emmanuel A., et al.
Publicado: (2016)

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Salivary Cytokines in patients with Head and Neck Cancer (HNC) treated with Radiotherapy
por: Principe, Sara, et al.
Publicado: (2019)

Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
por: Ferris, Robert L, et al.
Publicado: (2014)

Motolimod, a selective TLR8 agonist induces apoptosis in monocytic myeloid-derived suppressor cells (M-MDSC)
por: Rutnam, Zina J, et al.
Publicado: (2015)

BMSC–HNC Interaction: Exploring Effects on Bone Integrity and Head and Neck Cancer Progression
por: Eichberger, Jonas, et al.
Publicado: (2023)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Psychosocial Distress of Head Neck Cancer (HNC) Patients Receiving Radiotherapy: A Systematic Review
por: Nayak, Shalini G, et al.
Publicado: (2022)

Motolimod effectively drives immune activation in advanced cancer patients
por: Dietsch, Gregory N.
Publicado: (2016)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

Health-related quality of life up to 1 year after radiotherapy in patients with head and neck cancer (HNC)
por: Loorents, Vera, et al.
Publicado: (2016)

Young population awareness of head and neck cancer's (HNC) risk factors, symptoms and prognosis – a pilot survey
por: Krentowska, Anna, et al.
Publicado: (2015)

Interventions to improve quality of life (QOL) and/or mood in patients with head and neck cancer (HNC): a review of the evidence
por: Senchak, Jordan J., et al.
Publicado: (2019)

What are the optimal measures to identify anxiety and depression in people diagnosed with head and neck cancer (HNC): a systematic review
por: Shunmugasundaram, Chindhu, et al.
Publicado: (2020)

T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response
por: Kansy, Benjamin A., et al.
Publicado: (2018)

Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
por: Srivastava, Raghvendra M, et al.
Publicado: (2015)

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT
por: Theodoraki, Marie-Nicole, et al.
Publicado: (2019)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Randomized Phase III Trial of Adjuvant Chemotherapy with S-1 after Curative Treatment in Patients with Squamous-Cell Carcinoma of the Head and Neck (ACTS-HNC)
por: Tsukahara, Kiyoaki, et al.
Publicado: (2015)

Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study
por: Kubota, Akira, et al.
Publicado: (2018)

Simultaneous Integrated Boost (SIB) vs. Sequential Boost in Head and Neck Cancer (HNC) Radiotherapy: A Radiomics-Based Decision Proof of Concept
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023)

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
por: Pogorzelski, Michael, et al.
Publicado: (2021)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)
por: Guan, Jian, et al.
Publicado: (2016)

Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study
por: Liu, Gang, et al.
Publicado: (2020)

Correlation between Tissue Cellularity and Metabolism Represented by Diffusion-Weighted Imaging (DWI) and 18F-FDG PET/MRI in Head and Neck Cancer (HNC)
por: Freihat, Omar, et al.
Publicado: (2022)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j9b5br0bjp0rjnsdeo0anp3f5j